Zicronapine exhibits monoaminergic activity and has a multi-receptorial profile. ''In vitro'' and ''in vivo'' it has shown potent antagonistic effects at dopamine [[Dopamine receptor D1|D<sub>1</sub>]], [[Dopamine receptor D2|D<sub>2</sub>]] and serotonin [[5-HT2A receptor|5HT<sub>2A</sub>]] receptors.<ref>{{cite web|title=Zicronapine shows significant positive data in clinical phase II in the treatment of patients with schizophrenia - planning for continued clinical work|url=http://investor.lundbeck.com/releasedetail.cfm?ReleaseID=608605|accessdate=6 February 2014|date=December 18, 2009}}</ref>
